BioMarin Pharmaceutical Enters Settlement & License Agreement with Ascendis

What Happened BioMarin Pharmaceutical Inc. announced on September 30, 2026 (reporting an agreement dated September 24, 2026, effective August 28, 2026) that it entered into a Settlement and License Agreement with Ascendis Pharma A/S. BioMarin granted Ascendis a non-exclusive, worldwide, transferable, royalty-bearing license to certain BioMarin patent rights covering TransCon CNP (also called navepegritide or Yuviwel) to research, develop, manufacture, use, sell and commercialize Licensed Products for all current and potential indications, including achondroplasia and hypochondroplasia.

Key Details

• Agreement effective date: August 28, 2026; executed September 24, 2026; supersedes the August 31, 2026 term sheet previously reported.
• Royalty terms: 20% of annual net sales in the United States; 18% of annual net sales in the European Union, Brazil and South Korea. Royalties apply from the date of first commercial sale in each territory (retroactively as applicable) and run until May 2030.
• Litigation: The parties will dismiss with prejudice all pending litigation between them relating to the BioMarin Patent Rights.
• Additional terms: mutual regulatory non-interference, Ascendis covenant not to challenge the patents, BioMarin release of pre-Effective Date infringement claims and a covenant not to sue Ascendis for infringement.

Why It Matters This agreement converts BioMarin’s patent position into potential near-term royalty income tied to Ascendis’s commercialization of TransCon CNP, while removing ongoing litigation risk between the companies. For investors, the agreement defines clear royalty rates and territories but limits BioMarin’s royalty stream to May 2030 and depends entirely on Ascendis’s commercial success and timing of first sales. The filing also notes customary forward-looking risks and makes no guarantees about actual future sales or payments.